February 19, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  Fenofibrate and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/February/2019, `3.13 pm

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem […]
February 18, 2019

Molecular therapy for Diabetes Mellitus: Dapagliflozin (trade name: Forxiga, & Farxiga), a sodium glucose cotransporter-2 inhibitor used in the treatment of TIIDM, augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 18/February/2019, 2.57 pm

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
February 18, 2019

Neurotrophic factor-based therapy for Autoimmune diabetes: Mesencephalic astrocyte-derived neurotrophic factor (MANF) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 18/February/2019, 2.50 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical […]
February 18, 2019

Combinatorial therapy for glioblastoma: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) [SAN] inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down-regulation of its target gene, 18/February/2019, 1.07 pm

Introduction: What they say:  A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors […]